 Robert Dietz
Concepts (178)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypothermia, Induced | 6 | 2023 | 90 | 3.430 |
Why?
| | Hypoxia-Ischemia, Brain | 4 | 2023 | 39 | 2.650 |
Why?
| | Brain Ischemia | 10 | 2025 | 343 | 2.570 |
Why?
| | Hippocampus | 12 | 2025 | 929 | 1.440 |
Why?
| | TRPM Cation Channels | 3 | 2021 | 74 | 1.390 |
Why?
| | Recovery of Function | 4 | 2025 | 665 | 1.230 |
Why?
| | Heart Arrest | 6 | 2025 | 383 | 1.180 |
Why?
| | Asphyxia Neonatorum | 2 | 2018 | 18 | 1.050 |
Why?
| | Cerebral Palsy | 2 | 2018 | 113 | 0.950 |
Why?
| | Neurons | 8 | 2019 | 1602 | 0.850 |
Why?
| | Ischemia | 3 | 2023 | 414 | 0.800 |
Why?
| | Infant, Newborn, Diseases | 1 | 2023 | 115 | 0.740 |
Why?
| | Dexmedetomidine | 1 | 2022 | 42 | 0.730 |
Why?
| | Magnesium Sulfate | 2 | 2018 | 19 | 0.700 |
Why?
| | Cortical Spreading Depression | 3 | 2010 | 9 | 0.680 |
Why?
| | Long-Term Potentiation | 6 | 2025 | 199 | 0.680 |
Why?
| | Intensive Care Units, Neonatal | 2 | 2020 | 260 | 0.640 |
Why?
| | Intensive Care, Neonatal | 1 | 2020 | 40 | 0.640 |
Why?
| | Infant, Newborn | 10 | 2023 | 6159 | 0.610 |
Why?
| | Hypothermia | 1 | 2018 | 39 | 0.580 |
Why?
| | Brain-Derived Neurotrophic Factor | 2 | 2019 | 140 | 0.560 |
Why?
| | Community-Acquired Infections | 1 | 2020 | 173 | 0.560 |
Why?
| | Peptide Fragments | 1 | 2021 | 694 | 0.540 |
Why?
| | Zinc | 3 | 2010 | 299 | 0.540 |
Why?
| | Cognitive Dysfunction | 2 | 2019 | 392 | 0.530 |
Why?
| | Membrane Glycoproteins | 1 | 2018 | 501 | 0.460 |
Why?
| | Tinea | 1 | 2014 | 2 | 0.450 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2018 | 431 | 0.440 |
Why?
| | Calcium | 4 | 2017 | 1189 | 0.430 |
Why?
| | Exanthema | 1 | 2014 | 80 | 0.420 |
Why?
| | Premature Birth | 1 | 2017 | 343 | 0.420 |
Why?
| | Resuscitation | 1 | 2016 | 275 | 0.400 |
Why?
| | Animals | 24 | 2025 | 37261 | 0.370 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1570 | 0.370 |
Why?
| | Immunity, Innate | 1 | 2017 | 827 | 0.360 |
Why?
| | Oxidative Stress | 1 | 2017 | 1318 | 0.340 |
Why?
| | Gonadal Steroid Hormones | 2 | 2025 | 140 | 0.340 |
Why?
| | Hospitalization | 1 | 2020 | 2233 | 0.320 |
Why?
| | Neuronal Plasticity | 4 | 2023 | 302 | 0.310 |
Why?
| | Mice, Inbred C57BL | 9 | 2025 | 5805 | 0.310 |
Why?
| | Cardiopulmonary Resuscitation | 3 | 2025 | 324 | 0.300 |
Why?
| | Mice | 16 | 2025 | 17836 | 0.290 |
Why?
| | CA1 Region, Hippocampal | 2 | 2019 | 52 | 0.280 |
Why?
| | Infant, Premature | 3 | 2018 | 580 | 0.280 |
Why?
| | Sodium-Calcium Exchanger | 1 | 2007 | 16 | 0.260 |
Why?
| | Stroke | 3 | 2022 | 1140 | 0.260 |
Why?
| | Cognition | 3 | 2019 | 1179 | 0.250 |
Why?
| | Dendrites | 1 | 2007 | 103 | 0.240 |
Why?
| | Humans | 17 | 2023 | 139072 | 0.210 |
Why?
| | Infant | 4 | 2019 | 9586 | 0.200 |
Why?
| | Multiple Organ Failure | 1 | 2023 | 126 | 0.200 |
Why?
| | Cerebral Infarction | 1 | 2022 | 49 | 0.190 |
Why?
| | Male | 16 | 2025 | 68299 | 0.190 |
Why?
| | Cerebellar Diseases | 1 | 2022 | 24 | 0.180 |
Why?
| | Organ Culture Techniques | 1 | 2021 | 157 | 0.180 |
Why?
| | Blood-Brain Barrier | 1 | 2022 | 141 | 0.170 |
Why?
| | Female | 12 | 2025 | 74071 | 0.170 |
Why?
| | Morphine | 1 | 2022 | 171 | 0.170 |
Why?
| | Memory Disorders | 2 | 2019 | 177 | 0.170 |
Why?
| | Brain | 2 | 2023 | 2794 | 0.170 |
Why?
| | Chelating Agents | 3 | 2010 | 74 | 0.160 |
Why?
| | Nogo Proteins | 1 | 2019 | 10 | 0.150 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2019 | 73 | 0.150 |
Why?
| | Heparitin Sulfate | 1 | 2019 | 45 | 0.150 |
Why?
| | Membrane Potentials | 3 | 2010 | 283 | 0.150 |
Why?
| | Brain Injuries | 2 | 2017 | 500 | 0.150 |
Why?
| | Calcineurin | 1 | 2019 | 107 | 0.150 |
Why?
| | Nerve Net | 1 | 2021 | 268 | 0.140 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2020 | 185 | 0.140 |
Why?
| | Standard of Care | 1 | 2018 | 77 | 0.140 |
Why?
| | Ouabain | 2 | 2008 | 18 | 0.140 |
Why?
| | Aging | 2 | 2019 | 1857 | 0.140 |
Why?
| | Lateral Ventricles | 1 | 2018 | 32 | 0.140 |
Why?
| | Myelin Proteolipid Protein | 1 | 2018 | 60 | 0.140 |
Why?
| | Magnesium | 1 | 2017 | 158 | 0.130 |
Why?
| | In Vitro Techniques | 3 | 2008 | 1092 | 0.130 |
Why?
| | Hyperoxia | 1 | 2017 | 91 | 0.130 |
Why?
| | Infant, Premature, Diseases | 1 | 2018 | 105 | 0.130 |
Why?
| | Neuroprotection | 1 | 2017 | 43 | 0.130 |
Why?
| | Calcium Channel Blockers | 2 | 2008 | 172 | 0.130 |
Why?
| | Mice, Knockout | 3 | 2019 | 3029 | 0.120 |
Why?
| | Age Factors | 2 | 2021 | 3276 | 0.120 |
Why?
| | Disease Models, Animal | 3 | 2022 | 4319 | 0.120 |
Why?
| | Axons | 1 | 2018 | 195 | 0.120 |
Why?
| | Myelin Sheath | 1 | 2018 | 164 | 0.120 |
Why?
| | Calcium Channels, T-Type | 1 | 2017 | 106 | 0.120 |
Why?
| | Excitatory Postsynaptic Potentials | 1 | 2016 | 124 | 0.120 |
Why?
| | Macaca mulatta | 1 | 2016 | 186 | 0.110 |
Why?
| | Neuroprotective Agents | 1 | 2016 | 138 | 0.110 |
Why?
| | Signal Transduction | 2 | 2019 | 5095 | 0.110 |
Why?
| | Pregnancy | 2 | 2018 | 6872 | 0.110 |
Why?
| | Lung Injury | 1 | 2017 | 224 | 0.110 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2017 | 185 | 0.110 |
Why?
| | History, 20th Century | 1 | 2016 | 324 | 0.110 |
Why?
| | Behavior, Animal | 1 | 2018 | 512 | 0.110 |
Why?
| | Action Potentials | 1 | 2017 | 485 | 0.110 |
Why?
| | Intestinal Atresia | 1 | 2014 | 15 | 0.110 |
Why?
| | Enzyme Inhibitors | 2 | 2008 | 850 | 0.110 |
Why?
| | Animals, Newborn | 1 | 2016 | 859 | 0.100 |
Why?
| | Intestine, Small | 1 | 2014 | 156 | 0.100 |
Why?
| | Sepsis | 1 | 2019 | 612 | 0.100 |
Why?
| | Brain Injuries, Traumatic | 1 | 2018 | 380 | 0.090 |
Why?
| | Mitochondria | 2 | 2009 | 958 | 0.090 |
Why?
| | Abnormalities, Multiple | 1 | 2014 | 195 | 0.090 |
Why?
| | Urinary Bladder | 1 | 2014 | 186 | 0.090 |
Why?
| | Colon | 1 | 2014 | 284 | 0.090 |
Why?
| | Peptides | 1 | 2016 | 980 | 0.080 |
Why?
| | Colorado | 1 | 2020 | 4555 | 0.080 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2016 | 2049 | 0.080 |
Why?
| | Adenosine A1 Receptor Antagonists | 1 | 2008 | 2 | 0.070 |
Why?
| | Ethylenediamines | 1 | 2008 | 6 | 0.070 |
Why?
| | Sodium-Potassium-Exchanging ATPase | 1 | 2008 | 55 | 0.070 |
Why?
| | Electrophysiology | 1 | 2008 | 217 | 0.070 |
Why?
| | Potassium | 1 | 2008 | 147 | 0.070 |
Why?
| | Mice, Inbred Strains | 1 | 2008 | 411 | 0.070 |
Why?
| | Calcium Channels, L-Type | 1 | 2008 | 117 | 0.070 |
Why?
| | Nimodipine | 1 | 2007 | 6 | 0.070 |
Why?
| | Calcium Signaling | 1 | 2009 | 250 | 0.070 |
Why?
| | N-Methylaspartate | 1 | 2007 | 43 | 0.060 |
Why?
| | Excitatory Amino Acid Agonists | 1 | 2007 | 41 | 0.060 |
Why?
| | Glucose | 2 | 2010 | 1032 | 0.060 |
Why?
| | Carrier Proteins | 1 | 2010 | 738 | 0.060 |
Why?
| | Patch-Clamp Techniques | 1 | 2007 | 291 | 0.060 |
Why?
| | Sodium | 1 | 2007 | 196 | 0.060 |
Why?
| | Treatment Outcome | 1 | 2020 | 10930 | 0.060 |
Why?
| | Rats, Sprague-Dawley | 2 | 2023 | 2499 | 0.060 |
Why?
| | Ovariectomy | 1 | 2025 | 157 | 0.050 |
Why?
| | Membrane Proteins | 1 | 2010 | 1149 | 0.050 |
Why?
| | Endocarditis, Bacterial | 1 | 2004 | 45 | 0.050 |
Why?
| | Aged | 1 | 2022 | 24186 | 0.050 |
Why?
| | Retrospective Studies | 1 | 2020 | 15919 | 0.050 |
Why?
| | Rats | 2 | 2023 | 5594 | 0.050 |
Why?
| | Sex Factors | 2 | 2018 | 2052 | 0.040 |
Why?
| | Hypoxia | 1 | 2008 | 1150 | 0.040 |
Why?
| | Hypnotics and Sedatives | 1 | 2023 | 211 | 0.040 |
Why?
| | Blood Platelets | 1 | 2004 | 427 | 0.040 |
Why?
| | Cerebellum | 1 | 2022 | 218 | 0.040 |
Why?
| | Staphylococcal Infections | 1 | 2004 | 387 | 0.040 |
Why?
| | Thalamic Nuclei | 1 | 2018 | 9 | 0.040 |
Why?
| | Oligodendrocyte Precursor Cells | 1 | 2018 | 19 | 0.030 |
Why?
| | Long-Term Synaptic Depression | 1 | 2018 | 55 | 0.030 |
Why?
| | Memory | 1 | 2019 | 258 | 0.030 |
Why?
| | Receptors, AMPA | 1 | 2018 | 140 | 0.030 |
Why?
| | Receptors, GABA-A | 1 | 2017 | 141 | 0.030 |
Why?
| | Brain Infarction | 1 | 2016 | 23 | 0.030 |
Why?
| | Time Factors | 2 | 2017 | 6869 | 0.030 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2017 | 196 | 0.030 |
Why?
| | Rats, Wistar | 1 | 2017 | 453 | 0.030 |
Why?
| | Microglia | 1 | 2018 | 256 | 0.030 |
Why?
| | Cell Death | 1 | 2017 | 375 | 0.030 |
Why?
| | Cerebral Cortex | 1 | 2018 | 452 | 0.030 |
Why?
| | Prune Belly Syndrome | 1 | 2014 | 8 | 0.030 |
Why?
| | Transfection | 1 | 2016 | 942 | 0.030 |
Why?
| | Anti-Bacterial Agents | 1 | 2004 | 1819 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2016 | 731 | 0.030 |
Why?
| | Syndrome | 1 | 2014 | 377 | 0.020 |
Why?
| | Phosphorylation | 1 | 2017 | 1767 | 0.020 |
Why?
| | Radiography | 1 | 2014 | 841 | 0.020 |
Why?
| | Hypoxia, Brain | 1 | 2010 | 9 | 0.020 |
Why?
| | Edetic Acid | 1 | 2010 | 50 | 0.020 |
Why?
| | Potassium Chloride | 1 | 2010 | 42 | 0.020 |
Why?
| | Polycyclic Compounds | 1 | 2010 | 14 | 0.020 |
Why?
| | Indicators and Reagents | 1 | 2010 | 110 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2018 | 2482 | 0.020 |
Why?
| | Pyramidal Cells | 1 | 2010 | 73 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2022 | 3640 | 0.020 |
Why?
| | Cation Transport Proteins | 1 | 2010 | 109 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 1482 | 0.020 |
Why?
| | Membrane Transport Proteins | 1 | 2010 | 154 | 0.020 |
Why?
| | Fluorescent Dyes | 1 | 2010 | 320 | 0.020 |
Why?
| | Nafcillin | 1 | 2004 | 3 | 0.010 |
Why?
| | Penicillins | 1 | 2004 | 59 | 0.010 |
Why?
| | Staphylococcus | 1 | 2004 | 75 | 0.010 |
Why?
| | Vancomycin | 1 | 2004 | 82 | 0.010 |
Why?
| | Microbial Sensitivity Tests | 1 | 2004 | 351 | 0.010 |
Why?
| | Rabbits | 1 | 2004 | 762 | 0.010 |
Why?
| | Heart | 1 | 2004 | 612 | 0.010 |
Why?
| | Child | 1 | 2019 | 21946 | 0.010 |
Why?
|
|
Dietz's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|